Not Yet RecruitingNot Applicable

One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation

30 participantsStarted 2026-04-01

Plain-language summary

Using RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ablation treatment of the lesion.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years, male or female. * High-risk pulmonary nodule/tumor maximum diameter ≤3 cm. * Lesion judged suitable for bronchial navigation-guided diagnosis and treatment. * Ineligible for surgery or refuses surgery/radiotherapy; agrees to primary ablation therapy; provides written informed consent. Exclusion Criteria: * Diffuse bilateral lung lesions unresponsive to ablation. * Contraindication to bronchoscopy or inability to tolerate/cooperate with bronchoscopy. * Severe bleeding tendency or irreversible coagulopathy (PT \>18 s, PTA \<40%).Platelet count \<70×10⁹/L; anticoagulant/antiplatelet therapy discontinued \<1 week before ablation (except prophylactic low-molecular-weight heparin). * Severe pulmonary impairment (maximal voluntary ventilation \<40%). * Other metastatic tumors with widespread metastasis; life expectancy \<3 months. * Poor general condition: widespread metastasis, severe infection, high fever, infectious/radiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic/nutritional disorders. * Eastern Cooperative Oncology Group (ECOG) performance status \>2. * Target lesion received radiotherapy within the past 6 months. * Active hepatitis B, active hepatitis C, known HIV-1/2 antibody positivity, or other active infections judged by the investigator to interfere with treatment. * History of epilepsy, psychosis, or cognitive impairment. * Pregnant/lactating females; males…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Integrated completion rate of detection, sampling and treatment

Timeframe: Day 1 (when the procedure was completed and a CBCT scan was conducted to determine the ablation range)

Trial details

NCT IDNCT07521618

SponsorGuangzhou Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

Changhao Zhong

02081566640 vast1982@126.com

View on ClinicalTrials.gov More Lung Cancer (Suspected or Confirmed) trials